Interleukin receptor family member ST2 concentrations in patients following heart transplantation

Biomarkers

Volumn 18, Issue 3, 2013, Pages 250-256

  Januzzi, James L ^a   Horne, Benjamin D ^b   Moore, Stephanie A ^a   Galenko, Oxana ^c   Snow, Gregory L ^b   Brunisholz, Kimberly D ^b   Muhlestein, Joseph B ^b   Alharethi, Rami ^b   Carlquist, John F ^c   Budge, Deborah ^b   Rasmussen, Kismet ^b   Kfoury, Abdallah G ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b INTERMOUNTAIN MEDICAL CENTER   (United States)

^c LDS HOSPITAL   (United States)

Author keywords

Biomarkers; Biopsy; Heart transplantation; Prognosis; Rejection

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INTERLEUKIN RECEPTOR; INTERLEUKIN RECEPTOR ST2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CARDIOVASCULAR MORTALITY; FEMALE; FOLLOW UP; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN BLOOD LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, CELL SURFACE; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84876535969     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2013.773081     Document Type: Article

References (21)

1. Brint EK, Xu D, Liu H, et al. (2004). ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 5: 373-9. (Pubitemid 38500085)
2. Brunner M, Krenn C, Roth G, et al. (2004). Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med 30: 1468-73. (Pubitemid 38951733)
3. Dieplinger B, Januzzi Jr JL, Steinmair M, et al. (2009). Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma-the Presage ST2 assay. Clin Chim Acta 409: 33-40.
4. Januzzi Jr JL, Peacock WF, Maisel AS, et al. (2007). Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department). study. J Am Coll Cardiol 50: 607-13. (Pubitemid 47199007)
5. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al. (2011). Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 30: 252-69.
6. Liu J, Buckley JM, Redmond HP, Wang JH. (2010). ST2 negatively regulates TLR2 signaling, but is not required for bacterial lipoprotein-induced tolerance. J Immunol 184: 5802-8.
7. Pascual-Figal DA, Garrido IP, Blanco R, et al. (2011). Soluble ST2 is a marker for acute cardiac allograft rejection. Ann Thorac Surg 92: 2118-24.
8. Pietra BA, Wiseman A, Bolwerk A, et al. (2000). CD4 T cell-mediated cardiac allograft rejection requires donor but not host MHC class II. J Clin Invest 106: 1003-10.
9. Rehman SU, Mueller T, Januzzi Jr JL. (2008). Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 52: 1458-65.
10. Sabatine MS, Morrow DA, Higgins LJ, et al. (2008). Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 117: 1936-44. (Pubitemid 351543469)
11. Sanada S, Hakuno D, Higgins LJ, et al. (2007). IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 117: 1538-49. (Pubitemid 46871338)
12. Schmitz J, Owyang A, Oldham E, et al. (2005). IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479-90. (Pubitemid 41587888)
13. Seki K, Sanada S, Kudinova AY, et al. (2009). Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2: 684-91.
14. Shah RV, Chen-Tournoux AA, Picard MH, et al. (2009). Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail 2: 311-19.
15. Stewart S, Winters GL, Fishbein MC, et al. (2005). Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 24: 1710-20. (Pubitemid 41641841)
16. Tay SS, Plain KM, Bishop GA. (2009). Role of IL-4 and Th2 responses in allograft rejection and tolerance. Curr Opin Organ Transplant 14: 16-22.
17. Turnquist HR, Sumpter TL, Tsung A, et al. (2008). IL-1beta-driven ST2L expression promotes maturation resistance in rapamycinconditioned dendritic cells. J Immunol 181: 62-72.
18. Waaga AM, Gasser M, Kist-Van Holthe JE, et al. (2001). Regulatory functions of self-restricted MHC class II allopeptide-specific Th2 clones in vivo. J Clin Invest 107: 909-16. (Pubitemid 32274044)
19. Wang J, Guo Z, Dong Y, et al. (2003). Role of 4-1BB in allograft rejection mediated by CD8\+ T cells. Am J Transplant 3: 543-51. (Pubitemid 36612837)
20. Weir RA, Miller AM, Murphy GE, et al. (2010). Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol 55: 243-50.
21. Yin H, Li XY, Jin XB, et al. (2010). IL-33 prolongs murine cardiac allograft survival through induction of TH2-type immune deviation. Transplantation 89: 1189-97.